EpiVax employs a “Gene-to-Vaccine” design approach for the development of safer, more effective biodefense vaccines against potential bio-warfare agents. Epitopes provide the essential information required to trigger a protective immune response. Our suite of computational tools (EpiMatrix, Conservatrix, etc.) identifies T cell epitopes of interest that we then validate in vitro and in vivo, for use in final vaccine constructs. We are developing several epitope-based vaccines, including Smallpox, Tularemia, TB, H. Pylori, and Influenza.
We are dedicated to applying our tools (in-silico, in-vitro and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines. For a recent interview highlighting our CEO’s latest ideas, click on the video: